Trials / Completed
CompletedNCT01432730
A Study to Assess the Efficacy of Gefapixant (MK-7264/AF-219), in Participants With Chronic Cough (MK-7264-006)
A Study to Assess the Efficacy of AF-219, a P2X3 Receptor Antagonist, in Subjects With Chronic Cough (EPiCC)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomised, double-blind, placebo-controlled, crossover, single centre study of gefapixant (AF-219/MK-7264) in participants with idiopathic or treatment resistant chronic cough designed to evaluate the effectiveness of gefapixant in reducing daytime objective cough frequency.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gefapixant | Oral tablets, BID |
| DRUG | Placebo | Oral tablets, BID |
Timeline
- Start date
- 2011-09-22
- Primary completion
- 2013-02-07
- Completion
- 2013-02-21
- First posted
- 2011-09-13
- Last updated
- 2020-11-24
- Results posted
- 2020-11-02
Source: ClinicalTrials.gov record NCT01432730. Inclusion in this directory is not an endorsement.